A retrospective comparison of two cohorts, each with 108 patients, demonstrated that staging with PSMA-PET/CT without evidence of metastatic disease at BCR led to a 62% reduction in the relative risk of biochemical progression one year after salvage RT compared to “blind” salvage RT without conventional staging. Here, FOLH1 is linked to metastatic neoplasm.